BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also ...
BridgeBio's lead drug Attruby's approved for ATTR-CM last November has driven a 40% stock increase; however, competition and market dynamics may limit its near-term revenue potential. Despite ...
BridgeBio Pharma (NASDAQ:BBIO) has reached a pivotal turning point following the FDA approval of Attruby (acoramidis), an ...
BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...
Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. The Food and Drug ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...
The cost of Attruby can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Attruby. As with all medications, ...
Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby contains the active ingredient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results